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Abstract
The precursor protein, proopiomelanocortin (POMC), produces many biologically active peptides
via a series of enzymatic steps in a tissue-specific manner, yielding the melanocyte-stimulating
hormones (MSHs), corticotrophin (ACTH) and β-endorphin. The MSHs and ACTH bind to the
extracellular G-protein coupled melanocortin receptors (MCRs) of which there are five subtypes.
The MC3R and MC4R show widespread expression in the central nervous system (CNS), whilst
there is low level expression of MC1R and MC5R. In the CNS, cell bodies for POMC are mainly
located in the arcuate nucleus of the hypothalamus and the nucleus tractus solitarius of the
brainstem. Both of these areas have well defined functions relating to appetite and food intake.
Mouse knockouts (ko) for pomc, mc4r and mc3r all show an obese phenotype, as do humans
expressing mutations of POMC and MC4R. Recently, human subjects with specific mutations in β-
MSH have been found to be obese too, as have mice with engineered β-endorphin deficiency. The
CNS POMC system has other functions, including regulation of sexual behaviour, lactation, the
reproductive cycle and possibly central cardiovascular control. However, this review will focus on
feeding behaviour and link it in with the neuroanatomy of the POMC neurones in the hypothalamus
and brainstem.
Background
Over the last decade, there has been much research on the
role of hypothalamic POMC neurones, with regard to
appetite. However, POMC products (the MSHs, ACTH
and β-endorphin) also have important roles in the skin,
stress response, immune system and sexual function [1-6].
Experimental evidence suggests that POMC neurones
form an integral part of the central melanocortin system
regulating feeding behaviour. One or more of the melano-
cortins and β-endorphin, released from these POMC neu-
rones, may be involved in this regulation. When specific
genes in the CNS melanocortin system (POMC,  PC1,
MC4R and MC3R) are found mutated in either humans or
rodents, this results in an obese phenotype [7-9].
There have been two recent excellent reviews regarding the
electrophysiology of feeding circuits and the neuroanat-
omy of POMC [10,11]. However, the focus of this review
is the function of POMC projections in the CNS, which
originate from the arcuate nucleus of the hypothalamus
and the brainstem and their role in appetite and feeding
control. The review begins with a brief overview of feeding
systems and specifically the role of leptin as a major
peripheral signal to the POMC arcuate neurones. Then,
the basic biology of POMC and melanocortin receptors is
discussed, together with some observations from human
genetic studies. The next section deals with the two groups
of POMC neurones in the arcuate nucleus and brainstem,
as well as their melanocortin and β-endorphin products,
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MC4R, MC3R and feeding. This is set in the context of
other neurotransmitter systems that have been shown to
interact with the melanocortin system in these two brain
regions. Then other brain regions that might be targets for
POMC mediated effects are discussed, namely the par-
aventricular nucleus (PVN), lateral hypothalamus, dorso-
medial nucleus (DMH), supraoptic nucleus (SON),
ventromedial nucleus (VMH), periventricular nucleus,
nucleus accumbens and amygdala. As far as possible,
other interacting neurotransmitters are discussed in the
sections relating to where their cell bodies or projections
are located.
Feeding and energy homeostasis
Feeding is primarily a response to habitually entrained
rhythms, including circadian rhythms. Feeding behaviour
is regulated by a system with the hypothalamus at the cen-
tre, where how much we eat is a response to an internal
energy status [12]. There are complex but integrated inter-
connections between the hypothalamic nuclei that main-
tain energy homeostasis through regulation of food intake
and energy expenditure [13-16]. One of the key compo-
nents of the hypothalamic system is the POMC neurones
of the arcuate nucleus [10,11]. One of the main longer
term peripheral signals is the hormone leptin [10,11].
Leptin and hypothalamic regulation
The site of leptin's action is the mediobasal hypothala-
mus, principally the hypothalamic arcuate nucleus, via
the long form of the leptin receptor (LEPRB) that influ-
ences the activities of two separate groups of neurones
with opposing feeding functions. These include POMC
neurones that co-express CART and AgRP neurones that
co-express NPY. These arcuate POMC neurones have proc-
esses close to the fenestrated capillaries of the median
eminence and can thus be targeted by hormones such as
leptin in the circulation [17]. POMC neurones in the arcu-
ate nucleus, which express LEPRB, are activated by leptin.
They project to the DMH, PVN and lateral hypothalamus
[10,11]. Leptin may thus be the signal linking peripheral
energy stores with POMC signalling activity in the
hypothalamus. LEPRB is also expressed in many other
hypothalamic nuclei that may have a role in appetite.
These include the DMH, VMH, PVN, lateral hypothalamic
area, periventricular nucleus and SON [18,19]. It must be
remembered that not all mammalian hypothalamic
POMC neurones express leptin receptors [20,21], suggest-
ing the existence of a leptin-unrelated melanocortin sig-
nalling system too.
Proopiomelanocortin (POMC) genetics and its 
post-translational modification
POMC is the precursor of the MSHs and adrenocortico-
trophin (ACTH), as well as β-endorphin (Figure 1). The
MSHs and ACTH are collectively known as melanocortins.
All sequenced mammalian POMC genes consist of three
exons, interspersed by large introns (Figure 1; [22,23]).
pomc mRNA is synthesised in the pituitary, the arcuate
nucleus, the nucleus tractus solitarius of the brainstem
(NTS) and several peripheral tissues. This mRNA forms a
single protein, which passes to the Golgi bodies. The sig-
nal peptide sequence directs it into secretory granules
where post-translational processing yields many peptides
by successive, cell-specific, enzymatic modifications (Fig-
ure 1; [24-27]). Cleavage by the propeptide convertases
PC1 and PC2 occurs at specific pairs of basic residues, Lys
and Arg [28-30]. PC1 alone is expressed in the pituitary
corticotrophs and cleaves POMC, producing the NH2-ter-
minal peptide (NT), joining peptide (JP), ACTH, β-lipo-
trophin (β-LPH) and β-endorphin. Melanotrophs
generate PC1, PC2, carboxypeptidase E (CPE)), amidating
and  N-acetylating enzymes to produce α-MSH and β-
endorphin [28,29,31,32]. PC2 cleaves the first 14 amino
acidsof ACTH to generate ACTH (1–14) OH. PC2 cleaves
β-LPH to produce β-MSH and β-endorphin. The ACTH
(1–14) OH, after COOH-terminal amidation, produces
desacetyl-α-MSH, a step required for biologic activity. α-
N-acetylation of the NT enhances the action of α-MSH
and inhibits the action of β-endorphin [33]. O-acetylation
of α-MSH forms N,O-diacetyl-α-MSH. PC2 ko mice pro-
duce no α-MSH at all [34]. PC1 or PC2 may produce the
γ-MSHs but the mechanism is not clear [28,29]. Paired
amino-acid converting enzyme 4 (PACE4) colocalises
with POMC in the hypothalamus [35]. Both PACE4 and
POMC converting enzyme (PCE), a secretory vesicle
aspartyl protease, can cleave POMC in vitro [35,36]. How
these additional enzymes interact with PC1 and PC2 is
not clear at present. The subject of POMC processing in
the hypothalamus has been reviewed in more detail
recently [37].
The genetic pathology of the mammalian melanocortin 
system
POMC  deficiency in mice and humans and PC1
homozygous mutations in humans are characterised by
adrenal failure, early-onset obesity and, with POMC
mutations, altered pigmentation and tall stature [7,9,38].
Similarly, cpe ko mice show obesity, as well as a number
of other endocrine defects [27]. Subjects with the human
genetic obesity disorder, Prader-Willi syndrome, have
reduced levels of PC2 in their hypothalami on immuno-
cytochemical assessment [39].
A point mutation in the cleavage site between β-MSH and
β-endorphin (Figure 1) forms an aberrant fusion protein,
which causes obesity in humans, perhaps by altering cen-
tral melanocortin signalling in the CNS [40]. Hetero-
zygous mutations in MC4R also cause obesity and tall
stature in humans [7]. Recent data suggests that β-MSH
may be the important POMC product in inhibiting feed-Nutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
Page 3 of 16
(page number not for citation purposes)
ing centrally in humans [41], but not rodents, as rodents
do not produce β-MSH physiologically [7,42].
Mendelian human POMC disorders are very rare [43], but
there is linkage between POMC and other obesity related
traits, suggesting that it may form part of a common
genetic obesity predisposition [44,45]. These findings sug-
gest a clinically relevant role for POMC within the feeding
circuits in the CNS.
Melanocortin receptors (MCRs)
The melanocortins all contain the amino acid sequence
His-Phe-Arg-Trp, required for receptor occupancy. The
MCRs are part of the G-protein coupled receptor family.
Five MCRs are cloned, the MC1R, MC2R, MC3R, MC4R
and MC5R [46]. MC1R is predominantly the α-MSH
receptor and MC2R the ACTH receptor. In radioligand
binding studies, β-MSH shows more affinity to the MC4R
than α-MSH, with γ-MSH having the least affinity. γ-MSH
binds to the MC3R more than α- or β-MSH. MCR signal-
ling activates adenyl cyclase, leading to accumulation of
cAMP, as well as protein kinase C (PKC) and diacylglyc-
erol (DAG) downstream [1,46].
POMC neurones and the arcuate nucleus
The arcuate nucleus lies at the base of the hypothalamus.
It is responsive to peripheral stimuli such as leptin. Leptin
is essential in the neonatal phase for the development of
neuronal projections from the arcuate nucleus to the
DMH, PVN and lateral hypothalamus in succession, as
shown by DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindo-
carbocyanine perchlorate) axonal labelling [47].
POMC/CART and NPY/AgRP neuronal pathways from the 
arcuate nucleus
There are two main neuronal populations located in the
arcuate nucleus regulating appetite. There is evidence
from both gene and protein expression studies that the
Gene structure and post-translational processing of proopiomelanocortin (POMC) Figure 1
Gene structure and post-translational processing of proopiomelanocortin (POMC). POMC in mammals consists of 
3 exons, of which exons 2 and 3 are translated. Prohormone convertases 1 and 2 (PC1/2) break the parent POMC peptide into 
successively smaller peptides by cleavage at paired dibasic amino acid residues consisting of lysine (K) and/or arginine (R). The 
final products are generated in a tissue specific manner, for example α-MSH and ACTH are not produced by the same cells in 
the pituitary. They also involve additional enzymatic post translational modifications, such as the acetylation of α-MSH. The 
final products include the melanocortins (MSHs and ACTH), β-endorphin (β-end) and corticotrophin-like intermediate peptide 
(CLIP). There are intermediate peptides whose biological function remains unclear, such as β and γ lipotrophins (β-LPH, γ-
LPH).Nutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
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satiety neurones produce both POMC and cocaine and
amphetamine regulated transcript (CART) [48]. Food
restriction reduces hypothalamic pomc mRNA expression
[49], whereas hypothalamic pomc  mRNA expression is
increased in overfed rats [50]. The orexigenic neurones
contain NPY and agouti-related peptide (AgRP). Fasting
activates mRNA expression in hypothalamic NPY neu-
rones [51]. NPY is thought to be one of the strongest stim-
uli to feeding [51] perhaps partly acting by inhibiting
arcuate nucleus pomc mRNA expression via the Y2 receptor
[52]. The major function of AgRP is to stimulate feeding
by antagonising melanocortins at the MC3R and MC4R in
the hypothalamus [53]. Selective ablation of NPY/AgRP-
expressing neurones in adult mice results in acute reduc-
tion of feeding [54]. AgRP polymorphisms are associated
with inherited leanness in humans [55]. In the parvocel-
lular division of the paraventricular nucleus, close apposi-
tion of the perikarya of POMC/CART neurones and NPY/
AgRP-containing terminals is seen. CART arcuate nucleus
neurones markedly inhibit NPY-induced feeding in fasted
and normal rats [56].
Both the POMC/CART and NPY/AgRP pathways express
LEPRB and project to the leptin-dependent regions in the
DMH, PVN and lateral hypothalamus (Table 1).  Leptin
has opposite effects on each pathway with regard to feed-
ing, facilitating transmission in the POMC/CART system
and inhibiting the NPY/AgRP neurones, when measure by
a system using fluorescent protein (GFP)-tagged POMC
(red) and NPY (green) neurones  [57]. Surgical disruption
of the arcuate nucleus to PVN connection in rats results in
increased food intake and weight gain, including body fat,
implying that the balance of the background anorexigenic
effects of POMC/CART neurones is greater than the orexi-
genic effects of the NPY/AgRP neurones [58]. It must be
born in mind that lesioning experiments are likely to dis-
rupt many neuronal connections and their interpretation
requires some caution.
Using ob/ob mice expressing GFP on both POMC and NPY
neurones in the arcuate nucleus, leptin-deficiency has
been shown to increase both the number of excitatory
synapses to NPY/AgRP neurones and the number of
inhibitory synapses to POMC/CART neurones. When lep-
tin is given to the ob/ob mice, synaptic numbers revert to
the wild type pattern within 6 hours [57]. Fasting leads to
an increase in the action potential of the arcuate nucleus
NPY/AgRP neurones in normal mice, but this is not seen
in ob/ob or db/db strains lacking central leptin signalling
[59]. This leptin-induced neuronal plasticity may relate to
its role as a signal of fat stores. Melanotan II (MTII), an
MC3R/MC4R agonist reduces the orexigenic and adipo-
genic effects of NPY, but does not alter NPY-induced sup-
pression of the reproductive and growth neuroendocrine
axes [60]. A large proportion of NPY neurones in the rat
hypothalamus express mc3r mRNA while a much lower
number of NPY neurones express mc4r mRNA, suggesting
that POMC neurones may directly modulate the activity
of the hypothalamic NPY system too, mainly through acti-
vation of MC3R [61].
A subpopulation of arcuate nucleus NPY/AgRP/GABA-
producing neurones, identified immunocytochemically,
project to the PVN and send inhibitory GABA collaterals
to arcuate nucleus POMC neurones that express GFP [62].
GABA blocks the anorexic effect of icv α-MSH, whereas a
GABA antagonist increases the anorexia [63]. Thus, GABA
facilitates the feeding effect of NPY at target sites in the
PVN, by blocking opposing POMC transmission. How-
ever, in ob/ob mice (who congenitally lack leptin, leading
to obesity), leptin deficiency exaggerates the direct inhib-
itory effect of NPY neurones on POMC neurones in the
arcuate nucleus, an effect independent of the actions of
GABA [64]. Also, approximately one-third of POMC/
CART neurones express glutamic acid decarboxylase
(GAD) mRNA [47]. GAD is the enzyme necessary to pro-
duce GABA, although GABA is not thought to inhibit the
NPY/AgRP neurones and its exact function is unknown at
present. It may be involved more in the extra-hypotha-
lamic projections of POMC [65]. There is recent immuno-
cytochemical evidence that hypothalamic POMC
neurones express cholinergic fibres too [66]. Studies uti-
lising immuno-electron microscopy, immunocytochem-
istry and in-situ hybridisation show that both the NPY/
AgRP nerve fibres and the CART/POMC neurones are
innervated by glutaminergic fibres too [67,68]. This links
the control of feeding into wider feedback systems, for
example glutamate neurones connect to the VMH, DMH
and lateral hypothalamus, the other main feeding areas in
the hypothalamus [67,68].
Table 1: A summary of the experimental evidence for the 
presence of POMC axonal projections involved in feeding 
behaviour (axonal labelling vs immunocytochemistry – 
references indicated numerically)
Arcuate POMC 
projections:
Axonal 
labelling
Immunocytochemistry
Arcuate nucleus 57 48, 62, 93, 119
Brainstem 91 91
PVN - 62, 93
Lateral hypothalamus -9 3
DMH 160 93
SON -9 3
VMH -9 3
Periventricular nucleus - 93, 172
Nucleus accumbens -9 3
Amygdala -9 3Nutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
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AgRP – more than an antagonist of MC4R and MC3R?
The melanocortins have two endogenous antagonists,
agouti and AgRP, that show some subtype selectivity as
MCR antagonists. AgRP only acts on the CNS receptors,
MC4R and MC3R (Table 2; [69]). Both AgRP and the
MSHs can bind to MC3R and MC4R either presynaptically
or postsynaptically [10,11]. Like POMC, AgRP may
undergo post-translational processing [70]. Both agouti
and AgRP function as inverse agonists in vitro, so they
may regulate their respective MCRs in vivo, even in the
absence of melanocortins [71].
In hamsters, central administration of AgRP increases
food hoarding more than food intake [72]. Does this sug-
gest species differences in the response to AgRP, or per-
haps actions other than pure antagonism of the
melanocortin anorexic signal? AgRP83–132 has been shown
to have effects in the mc4r  ko mouse, which could be
attributable to MC3R antagonism, or perhaps as yet
unknown effects on a different receptor system [73].
Perhaps AgRP neuronal activity is more directly linked to
metabolic change than POMC neuronal activity? In the
ob/ob mouse, agrp gene expression is increased 5–10 fold
compared with wild type [74,75], whereas the absence of
leptin only reduces pomc  gene expression by approxi-
mately two-fold [76]. Others have found that there is vir-
tually no change in hypothalamic pomc  expression in
either food restricted, fasted or leptin resistant (Zucker)
rats versus controls [70]. Overall this gives a picture of a
rather tonic anorexic signal from the POMC/CART neu-
rones, perhaps with a more finely tuned and responsive
orexigenic signal from the AgRP/NPY system? AgRP, its
interactions with the melanocortin system and other roles
has been well reviewed recently [70].
Peptide YY and POMC
Peptide YY (PYY) and NPY are part of the same peptide
family, acting via the Y-group of receptors. After a meal,
the gut releases PYY3–36 into the circulation, which crosses
the BBB and reduces food intake by suppressing NPY
release and increasing POMC release in the arcuate
nucleus [77-80]. PYY3–36 inhibits the action potential fir-
ing activity of arcuate POMC neurones, acting through
postsynaptic Y2 receptors [81]. However, mc4r ko, pomc
ko and normal mice have similar anorexia with PYY, sug-
gesting it can act independently of melanocortins too
[9,82]. This may seem paradoxical, but could relate to dif-
fering development of the hypothalamic NPY/PYY system
in the absence of pomc or mc4r from birth.
VGF, lethal yellow and POMC
VGF (non-acronymic) is a hypothalamic neuropeptide
coexpressed in POMC and NPY neurones, identified by
immunocytochemistry, in the arcuate nucleus [83]. Lethal
yellow is an inbred obese mouse strain, resulting from
overexpression of agouti, which then has excess AgRP-like
actions in the CNS [69]. vgf ko mice are lean with normal
food intake and increased oxygen consumption and loco-
motor activity at rest [83]. Crossing the vgf ko mouse with
ob/ob and lethal yellow mutants, improves the obesity of
the ob/ob mouse and prevents the lethal yellow obese phe-
notype. This suggests that the actions of VGF are down-
stream of AgRP and the melanocortins [83]. Arcuate
nucleus vgf mRNA expression is increased in hamsters in
experimental short photoperiod situations mimicking
winter, suggesting a feeding-related hibernation function
for VGF [84].
Galanin and POMC
Cells in the arcuate nucleus, DMH and PVN show galanin
immunocytochemical staining [85]. When injected icv, or
directly into the PVN, VMH and lateral hypothalamus,
galanin is mildly orexigenic, perhaps by facilitating NPY's
actions [85,86]. Galanin blocks arcuate neuronal firing in
those neurones expressing gal-r1 receptor mRNA, perhaps
via direct contact with arcuate nucleus POMC neurones
[87].
POMC neurones and the brainstem
POMC neurones in the NTS, expressing GFP, are activated
both by cholecystokinin (CCK) and by satiety induced by
feeding, as shown by immunocytochemical measurement
of Fos protein [88]. The MC3R/MC4R antagonist
SHU9119 administered icv prevents CCK-induced sup-
pression of feeding, whether administered into the third
or fourth ventricle [88]. This effect of CCK activating
POMC "GFP" NTS neurones is blocked by a CCK antago-
nist and also antagonised by endogenous opioids [89].
The dorsal motor nucleus of the vagus nerve (DMX), lying
next to the NTS, has the highest density of MC4R in the
brain [90] and may mediate the anorexia due to activation
of the NTS POMC neurones by CCK [88]. The DMX also
receives fibres from the arcuate nucleus POMC neurones,
as shown by immunocytochemistry (Table 1; [91]).
Vagotomy results in a slight reduction in food intake, but
no change in body weight. This is associated with activa-
tion on neurones in the NTS, as well as increased AgRP
and decreased POMC mRNA expression in the hypothala-
Table 2: Melanocortin receptors and their endogenous 
antagonists
Melanocortin 
receptor
Endogenous antagonist
MC1R Agouti
MC2R Agouti
MC3R Agouti, AgRP
MC4R Agouti, AgRP
MC5R ?Nutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
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mus [92]. Using immunocytochemistry to demonstrate
both POMC and AgRP fibres and in situ hybridisation to
show their MC4R and MC3R targets (Table 3), much of
the neuroanatomy of the melanocortin system has been
mapped [93]. Interestingly, there are no AgRP neurones
projecting to the POMC neurones in the brainstem [93].
The role of POMC neurones in the NTS and vagal afferents
to both sets of POMC cell bodies requires further study.
Leptin, POMC and the brainstem
LEPRB is found in several brainstem nuclei involved in the
control of food intake, such as the DMX, area postrema,
NTS, parabrachial, hypoglossal, trigeminal, lateral reticu-
lar and cochlear nuclei, locus coeruleus and inferior olive
[94]. Leptin injected into either the fourth or lateral ven-
tricles, or into the dorsal vagal complex (DMX, AP and
NTS), suppresses feeding [94]. This suggests that the
brainstem neurones are just as effective at mediating ano-
rexia as the hypothalamic neurones and, like POMC, are
direct targets for the action of leptin in the control of
energy homeostasis [94]. However, part of this effect may
be being mediated by hypothalamic arcuate nucleus
POMC cells, as retrograde tracing experiments showed
that a small percentage of these hypothalamic neurones
project to the dorsal vagal complex [91].
Also, when leptin is administered centrally it activates the
arcuate POMC neurones, but not the NTS neurones [95].
Recently, leptin has been shown to modulate taste sensa-
tion directly, via the taste receptors, as well as via the
brainstem [96]. Leptin could have a refining influence on
feeding, via its actions on taste receptors and brainstem
nuclei, but this is unlikely to involve brainstem POMC
neurones in the process.
MC4R and MC3R; feeding and obesity
MC4R, feeding and obesity
In contrast to the restricted distribution of the POMC neu-
rones, MC4R and MC3R are widely present throughout
the brain, although with different patterns of distribution
(Table 3). The evidence, either genetic or neuropharmaco-
logical, for the key role of MC4R in feeding and the patho-
genesis of obesity is as follows.
The most common monogenic forms of human obesity
are  MC4R  mutations [7]. Murine and human MC4R
homozygous mutants are obese and hyperphagic [97-
100]. Murine and human MC4R heterozygous mutants
are obese to a lesser extent. This shows sensitivity to quan-
titative variation in MC4R  expression [97,100], with
mechanisms such as poor cell-surface expression or intra-
cellular retention of the mutant receptors [101,102]. It is
also possible that genetic defects in the intracellular traf-
ficking mechanisms, required to present MC4R on the cell
surface, could also lead to human obesity [103]. Interest-
ingly, human MC4R gene variants have also been associ-
ated with a lack of physical activity [104].
mc4r  mRNA and MC4R protein is concentrated in the
feeding areas of the PVN, DMH and lateral hypothalamus
[90,105]. The obesity of the lethal yellow and viable yel-
low strains of mice is due to over-expressed agouti (with
AgRP-like actions) in the hypothalamus, having an antag-
onistic effect at the MC3R and MC4R receptor [106].
MC4R agonists reduce feeding in rodents, with antago-
nists having the opposite effect [107,108]. Finally, MC4R
agonists administered intranasally decrease bodyweight
in humans [109]. Also simple behavioural change, such as
scheduling meal times, can significantly reduce the ano-
rexic effect of MC3R/MC4R agonists in rats [110]. Perhaps
the MC4R receptor does integrate the anorexigenic signal
from leptin via the POMC neurones of the arcuate nucleus
and brainstem. However, it is unlikely to be the only path-
way. Double mutant ob/ob mc4r/mc4r ko mice show par-
tial leptin resistance when compared with ob/ob strains,
suggesting an alternate central anorexic signalling system
for leptin exists [111].
POMC neurones in the arcuate nucleus, acting on other
feeding areas such as the PVN via MC4R activation, may
Table 3: MC4R mRNA and protein expression and MC3R mRNA expression in CNS regions involved in appetite regulation. Potential 
targets for POMC and AgRP neurones (references indicated numerically).
MCR locations: MC4R mRNA MC4R GFP expression MC3R mRNA
Arcuate nucleus 90 105 93, 114, 118
Brainstem 90 105 -
PVN 90, 93 105 118
Lateral hypothalamus 90 105 118
DMH 90 105 118
SON 90 - -
VMH 90 105 118
Periventricular nucleus 90 105 118
Nucleus accumbens 90 105 -
Amygdala 90 105 118Nutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
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be the principal CNS conduit for leptin's peripheral satiety
signal.
MC3R, intra-arcuate connections and obesity
Similarly one can review the evidence, either genetic or
neuropharmacological, for the function of MC3R in the
pathogenesis of obesity.
mc3r  ko mice are obese with increased fat mass and
decreased lean body mass, but without hyperphagia, in
contrast to mc4r  ko mice. However, mice lacking both
mc3r and mc4r are more obese than mc4r ko mice alone
[112,113]. Also, the obesity of mc3r  ko mice is more
dependent on fat intake than that of the mc4r ko mice
[114]. Diet induced obesity in these two ko strains affects
insulin-sensitivity more adversely in the mc4r  ko mice
[114].  mc4r  ko mice do not respond to the anorectic
action of MTII [73]. MC3R gene variants are common in
humans, but they are not associated with obesity [115].
However, MC3R may mediate different responses to lep-
tin than MC4R. While leptin administration reduces food
intake in mc4r ko mice, mc3r ko mice do not show an ano-
rexic response to leptin. This suggests that the ability of
leptin to reduce food consumption depends more upon
MC3R, rather than MC4R [116].
The MC3R is particularly expressed on the arcuate
nucleus, including on the POMC/CART neurones
[117,118] and the AgRP/NPY neurones [61] and is also
more generally expressed in the CNS than the MC4R
[90,118]. α-MSH, β-MSH and γ2-MSH all activate differ-
ent neuronal targets within this nucleus [42]. However, it
should be noted that MC4R is found on the arcuate
nucleus too [90,105]. There are intra-arcuate POMC con-
nections, suggesting that MC3R may mediate an autofeed-
back mechanism in the arcuate nucleus (Tables 1 and 3;
[61,118,119]). Administration of a specific MC3R agonist
reduces the frequency of action potentials in POMC-con-
taining neurones in the arcuate nucleus, which supports
this hypothesis [62]. It is not yet known if any of these
observations are important with regard to feeding behav-
iour, but they may be important with regard to overall
control of POMC neural projections. Overall, the role of
MC3R in feeding behaviour and obesity is less clear than
for MC4R.
Proopiomelanocortin products and feeding
It is clear that one or more of the POMC products is
involved in the anorectic response, as mice lacking either
the whole coding region of POMC or the whole POMC
gene are obese [8,9]. While POMC is the precursor for at
least three melanocortin peptides, α-, β- and γ2-MSH (Fig-
ure 1), it has been widely assumed that α-MSH is the pre-
dominant ligand involved in appetite regulation in
mammals, apart from humans [41,120]. β-MSH is not
produced by rodents [7,120]. One impediment to com-
parative studies of melanocortin function is that it is very
difficult to distinguish between the MSHs by immunocy-
tochemistry, because of their similarity in core structure.
Also, POMC neurones may release more than one peptide
at any given synapse [42]. Finally, unprocessed POMC is
found in human cerebrospinal fluid (CSF), at a concentra-
tion 100 fold higher than that of ACTH and may have a
signalling role in the brain as well [121]. Obese leptin
resistant fa/fa rats and fasted (low leptin) wild type rats
have lower CSF levels of POMC than fed rodents [122]. It
should be noted that as leptin regulates POMC synthesis
and release, it is difficult to dissect the role of POMC turn-
over in the CSF [122].
α-MSH and desacetyl-α-MSH
α-MSH suppresses feeding in free-feeding or fasted
rodents, when administered centrally, as do its synthetic
analogues containing the core MCR binding sequence
[42,106,123,124]. Desacetyl-α-MSH, in which the N-ter-
minal serine remains unacetylated, is a major precursor of
α-MSH and is found widely in the brain [125]. Whilst not
being shown to activate hypothalamic neurones in vivo
[42], it binds to and activates both MC3R and MC4R in
vitro and has an anorectic effect at high doses in vivo
[123]. Leptin facilitates the acetylation of desacetyl-α-
MSH to the more active melanocortin, α-MSH [126]. Per-
haps a failure to acetylate desacetyl-α-MSH in mammals
could lead to obesity? This has not yet, however, been
demonstrated.
β-MSH and γ-MSH
In radioligand binding studies, β-MSH has a higher affin-
ity for the MC4R than α-MSH, with γ-MSH having the
lowest affinity. In contrast, γ-MSH binds to the MC3R
with higher affinity than either α-MSH or β-MSH [127]. It
should be noted that binding of a ligand to a receptor
does not necessarily correlate with biological activation of
the cell expressing the receptor. Two independent studies
have shown that β-MSH can have a suppressive effect on
feeding in rats free-feeding or fasted for 24 hours
[123,124], but this has not been found in one study look-
ing at rats fasted for 48 hours [42]. Perhaps this is because
β-MSH is not produced physiologically in rodents [7,120]
and so any observed effects could be through pharmaco-
logical activation of the MC4R? [123,124,127] In a recent
study in ko mice lacking pomc, central administration of
α-MSH, β-MSH and γ-MSH can all reduce food intake, but
only α-MSH actually reduces weight gain and significantly
reverses the obese phenotype of the ko mouse [120]. A
selective β-MSH-derived peptide agonist has been shown
to decrease food intake and weight gain in diet-induced
obese rats, but not MC4R-deficient mice [128]. This sug-
gests that the anorectic pharmacological action of this β-
MSH agonist in vivo is via the MC4R [128]. Recently, sev-Nutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
Page 8 of 16
(page number not for citation purposes)
eral missense mutations have been identified in human β-
MSH, associated with early-onset human obesity
[41,129], as well as a cleavage site mutation preventing
processing of POMC to β-MSH, which is also associated
with human obesity [40]. γ2-MSH has a delayed anorectic
effect in fasted rats [42]. These data are consistent with
MC4R being the principal anorectic receptor in mammals,
with either α-MSH or β-MSH being the principal ligands
depending upon species [7,41,120]. Perhaps the delayed
feeding effect of γ2-MSH reflects autostimulation of the
POMC neurones projecting to the PVN, where POMC
products bind to MC4R? Alternatively, it could reflect an
inhibitory action via MC3R on NPY neurones in the arcu-
ate nucleus [61]. It is possible that individual arcuate
POMC projections in mammals release different combi-
nations of peptides (MSHs or β-endorphin) at the differ-
ent hypothalamic and extra-hypothalamic sites with
which they synapse, as part of the complex integration of
feeding behaviour in the CNS [42].
Melanocortin-opioid interactions
β-endorphin is another post-translational product of
POMC and, together with the opioid peptides, the
enkephalins and dynorphin, acts at µ- and κ-receptors to
stimulate feeding [130-133]. Opioid antagonists block
NPY induced feeding [134]. β-endorphin ko mice gain 10–
15% more body weight than wild type after puberty [135].
Thus, there may be a more complementary interaction
between the various POMC peptides in the regulation of
feeding [136]. For example, it is possible that secretory
vesicles could contain both MSHs and β-endorphin,
which would have antagonistic effects on feeding. Immu-
nocytochemistry has been used to show that there are syn-
aptic connections between POMC and enkephalin
neurones in the arcuate nucleus [137]. Using techniques
already described in this article, the nucleus accumbens
has been shown to have a POMC projection from the
arcuate nucleus (Table 1; [93]). It also contains endog-
enous opioids which mediate the positive emotional
response to palatable foods such as sugar and fat. This
may be their main role in appetite control, as opioid-
evoked feeding is generally short lived [138].
POMC and the paraventricular nucleus of the 
hypothalamus
The PVN has both neuroendocrine and feeding roles. It
has two major subdivisions, magnocellular and parvocel-
lular, that fan either side of the roof of the 3rd ventricle.
There is immunocytochemical evidence that many of the
POMC neurones in the arcuate nucleus project to the PVN
(Table 1; [93]) where the mc4r mRNA is present in abun-
dance (Table 3; [90]). Surgical disruption of this pathway
leads to obesity [58]. Activation of MC4Rs decreases body
fat stores by reducing food intake and increasing energy
expenditure. To identify which sites of mc4r expression are
most relevant for mediating these effects, mice were gen-
erated with a loxP-modified, null mc4r allele (loxTB mc4r)
that can be reactivated by Cre-recombinase [139]. Mice
homozygous for the loxTB mc4r  allele do not express
MC4Rs and are very obese [139]. Restoration of normal
mc4r expression in the PVN and a subpopulation of amy-
gdala neurones, using sim1-Cre transgenic mice, pre-
vented 60% of the obesity [139]. Notably, increased food
intake was completely rescued while reduced energy
expenditure was unaffected. These experiments suggest
that MC4Rs in the PVN and/or the amygdala control food
intake, but that MC4Rs elsewhere control energy expend-
iture [139]. All three MSHs, plus MTII, induce IEG expres-
sion in this area, although it is not known to what extent
this reflects direct actions of the melanocortins (e.g., α-
MSH and β-MSH) within the PVN or indirect activation
(e.g.,  γ2-MSH) via the MC3R on the arcuate nucleus
POMC neurones projecting to the PVN [42,140]. The PVN
expresses LEPRB and is thus responsive to leptin [18,19].
Rats overfed postnatally, who are hyperleptinaemic,
acquire altered electrophysiological responses in the PVN
to α-MSH, AgRP, MTII, CART, melanin-concentrating hor-
mone (MCH) and NPY respectively [141]. Injection of α-
MSH, but not β-endorphin, into the PVN reduces POMC
gene expression in the arcuate nucleus, implying a nega-
tive feedback system involving melanocortins only [142].
Nesfatin-1, α-MSH and the PVN
Nesfatin-1 is a novel satiety molecule that is processed
from the nucleobindin2/nesfatin precursor molecule
[143,144] and its mRNA is distributed in hypothalamic
nuclei including the arcuate nucleus and PVN [145]. Nes-
fatin-1 concentrations are reduced in the PVN with fast-
ing. Central administration of leptin does not alter
nucleobindin2/nesfatin mRNA expression. Also, the sati-
ety effect of nesfatin-1 is not altered in Zucker rats with an
leprb mutation and prior administration of an anti-nesfa-
tin-1 antibody does not block leptin-induced anorexia.
This implies that leptin signalling is independent of nes-
fatin-1 signalling. In contrast, central administration of α-
MSH markedly stimulates nucleobindin2/nesfatin gene
expression in the PVN [145]. Prior administration of the
MC3R/MC4R antagonist SHU9119 abolishes nesfatin-1-
induced feeding suppression, but nesfatin-1 does not
show any direct agonistic action on MC3R or MC4R.
These observations suggest that nesfatin-1 signalling is
involved in a leptin-independent melanocortin signalling
pathway in the hypothalamus.
It is clear that the arcuate nucleus to PVN circuit is funda-
mental in the transmission of the satiety message in the
hypothalamus.Nutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
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Neuroendocrine targets for POMC products in the PVN
Significant proportions of neurones activated by α-MSH,
β-MSH and γ2-MSH project outside the BBB and are thus
presumed to be neuroendocrine in origin [42], such as
CRF and TRH. Fasting suppresses CRF release, which is
blocked by α-MSH [146] and melanocortins can induce
CRF gene transcription in some PVN CRF nerves express-
ing MC4R [147]. This suggests that CRF acts downstream
of the melanocortin system. TRH release is elicited by α-
MSH, whereas γ-MSH and AgRP inhibit TRH release.
MC4R and MC3R agonists mimic the effect of α-MSH and
γ-MSH respectively [148]. This implies that hypothalamic
TRH release is controlled by POMC and AgRP neurones.
In the POMC ko mouse, there is reduced pituitary TSH
and hypothalamic TRH production, but the thyroid gland
compensates, with elevated plasma T3 and T4 [149]. These
central effects of the melanocortins on the stress and thy-
roid axes suggest that POMC neurones may influence
peripheral metabolism, which will in turn indirectly affect
feeding behaviour.
POMC and the lateral hypothalamus
Damage to the lateral hypothalamus inhibits feeding,
reducing body weight [150]. The lateral hypothalamus
expresses leprb mRNA and is regulated by leptin through-
out development [151]. Consistent with the anorexigenic
role of hypothalamic POMC pathways, α-MSH, β-MSH
and γ2-MSH activate neurones in the more central hypoth-
alamic structures that are associated with satiety, rather
than in the lateral hypothalamus, which has an estab-
lished role in feeding [42,152]. However, both mc3r and
mc4r  mRNA are located in the lateral hypothalamus
(Table 3; [90,118]) and there is immunoreactive evidence
of both POMC and AGRP fibres projecting from the arcu-
ate nucleus to the lateral hypothalamus (Table 1; [93]), so
the lack of response to the MSHs administered icv is per-
haps surprising.
MCH and POMC
MCH causes hyperphagia, whether injected icv or directly
into the arcuate nucleus, PVN and DMH. This is achieved
in part by altering the balance of neuronal activity, favour-
ing NPY/AgRP release and reducing α-MSH/CART release
from arcuate neurones [152-154]. For example, in
hypothalamic explant experiments injection of MCH into
the hypothalamus increased the production of NPY and
AgRP and decreased the production of MSH and CART, as
measured by radioimmunoassay [153].
Orexins and POMC
Orexin expressing cells are located in the lateral, dorsal
and perifornical nuclei. They innervate the arcuate
nucleus, preoptic area, paraventricular nucleus of the tha-
lamus, septal nuclei, locus coeruleus and DMX in the
brainstem, as measured immunocytochemically. There is
also immunocytochemical evidence that orexin neurones
synapse with NPY/AgRP and POMC/CART neurones in
the arcuate nucleus. Microinjection of orexins into the
arcuate nucleus, PVN and lateral hypothalamus stimu-
lates feeding [155-157]. It is possible to measure the
action potential of individual living arcuate POMC neu-
rones in mouse brain slices, identified by GFP transgenic
tagging. Using whole cell patch clamp recordings, orexin
suppresses the spontaneous firing in these neurones, sug-
gesting that its appetite enhancing effects include an effect
in suppressing hypothalamic POMC neuronal activity
[158].
POMC and the dorsomedial nucleus of the 
hypothalamus
The DMH is an important leptin target, as it expresses
both leprb mRNA and protein [18,19]. Lesioning experi-
ments suggest that it has extensive projections to the PVN,
particularly portions involved in autonomic control
[159]. These experiments also show that lesions of this
nucleus produce hypophagia and reduce linear growth
[159]. Using techniques already described in this article,
there is evidence of POMC projections from the arcuate
nucleus to the DMH (Table 1; [93]) and both mc3r and
mc4r mRNA are found in this nucleus (Table 3; [90,118]).
Using a retrograde-labelled approach to measure axonal
transport, there is evidence that some of these projections
from the DMH to the PVN may be under the control of
POMC neurones originating in the arcuate nucleus [160].
Despite the presence of the MC3R, only α-MSH and β-
MSH induce IEG expression in the DMH when adminis-
tered icv. Very few of these neurones, which demonstrate
increased IEG activity, project outside the BBB [42]. In
mc4r ko mice, or lethal yellow mice overexpressing agouti,
NPY expression (but not galanin or POMC) is signifi-
cantly elevated in the DMH. This suggests that POMC may
normally inhibit NPY expression tonically in the DMH
and that AgRP may be a determinant of NPY release phys-
iologically [161]. The DMH has direct brainstem projec-
tions to the DMX, which has the highest density of MC4R
in the brain [90,162].
POMC and the supraoptic nucleus of the 
hypothalamus
The SON lies laterally in a bilateral position at the base of
the hypothalamus. The SON and the mPVN contain oxy-
tocin and vasopressin cells, which project to the posterior
pituitary, where these hormones are released [3,163]. All
three MSHs activate IEGs in the SON and coexpression
with fluorogold suggests that all of these targets activated
by α-MSH and γ2-MSH, as well as the vast majority of
those activated by β-MSH, project outside the blood-brain
barrier in the rat [42]. β-MSH is not a physiological ligand
of the MC4R in rodents which may explain this partialNutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
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effect [42]. The effect of γ2-MSH is rather surprising, given
the presence of the MC4R and the absence of the MC3R in
this nucleus (Table 3; [42]). Again, this may reflect indi-
rect activation, perhaps via an arcuate nucleus POMC neu-
ronal projection to the SON, as evidenced by
immunocytochemical detection of POMC fibres between
these nuclei and in situ hybridisation for MC3R in the
arcuate nucleus and MC4R in the SON (Table 1;
[90,93,118]). CCK co-expression in oxytocin neurones in
the SON occurs in rats on a normal diet only, rather than
a high fat diet [164]. MC4R alone is expressed in the SON
and MC4R ko mice are particularly prone to gaining
weight on a high fat diet, even when compared with ob/ob
mice [165]. Perhaps POMC products acting on the MC4R,
under dynamic antagonism from AgRP [93], form part of
the CCK pathway in the SON involved with fat intake?
POMC and the ventromedial nucleus of the 
hypothalamus
The VMH lies close to the DMH, arcuate nucleus and third
ventricle. The VMH has no known neuroendocrine projec-
tions [42], but lesioning experiments show that it is
involved in feeding behaviour in the rat [166]. The projec-
tion from the arcuate nucleus to the VMH is very sparse
and very few of these fibres are POMC neurones on
immunocytochemistry (Table 1; [93]). Despite this, mc3r
and mc4r mRNA are abundant (Table 3; [90,118]). MTII
increases neuronal firing in the VMH in vitro and this
effect is lessened by prior food deprivation [167]. Perhaps
free POMC in the CNS has a true neuroendocrine role and
is post-translationally processed locally by the VMH?
[121] This could explain the extensive expression of mc3r
and mc4r, despite the very limited POMC axonal presence
in the VMH.
Brain-derived neurotrophic factor, TrkB and POMC 
neurones
Brain-derived neurotrophic factor (BDNF) and its recep-
tor, TrkB, control neurodevelopment and synaptic plastic-
ity. TrkB-deficient humans show learning difficulties and
severe obesity [168]. bdnf-deficient heterozygous mice are
obese, with high leptin and insulin levels which correct
with diet alone [169]. bdnf mRNA or protein is expressed
in the VMH, DMH and lateral hypothalamus, but not the
arcuate nucleus [169,170]. Its expression is reduced in the
VMH of lethal yellow mice, whereas administration of
MTII increases BDNF expression in the VMH of wild type
mice. BDNF suppresses feeding and weight gain in MC4R
ko mice, so its anorexic actions lie downstream of POMC.
It is unlikely that BDNF modulates either CART/POMC or
NPY/AgRP neurones in the arcuate nucleus as there is no
trkb receptor mRNA expressed in this nucleus [170].
POMC and the periventricular nucleus of the 
hypothalamus
Cafeteria diet-induced obese rats have been shown to
have increased somatostatin protein content and gene
expression in the periventricular nucleus [171]. Using a
double-labelled immunocytochemical approach, arcuate
nucleus POMC neurones have been shown to project to
the majority of somatostatin perikarya in the periventricu-
lar nucleus [172]. This implies that the effects of somato-
statin on growth and body composition are under the
influence of the melanocortins [172]. Similarly, somato-
statin receptors are located on POMC arcuate nucleus
neurones, suggesting bidirectional communication [172].
These observations link the hypothalamic functions of
appetite and growth regulation.
POMC, the nucleus accumbens and the 
amygdala
There is immunocytochemical evidence that the nucleus
accumbens of the forebrain receives both POMC and
AgRP projections from the arcuate nucleus (Table 1; [93]),
as well as a dopamine projection which mediates the rein-
forcing effects of stimulants, like cocaine, amphetamine,
nicotine and caffeine [173-175]. Microinjection of musci-
mol, a GABAA  receptor agonist, into the nucleus
accumbens, increases feeding. This is associated with acti-
vation of orexin neurones (but not MCH) in the lateral
hypothalamus and the activation of the NPY/AgRP projec-
tion and inhibition of the POMC/CART projection in the
Arc [176]. This may be a mechanism for the appetite mod-
ulating effects of cocaine, amphetamine, nicotine and caf-
feine.
The amygdala, located in the mid-temporal lobe, assigns
emotional significance to sensory information, such as
fear-related responses [177]. It receives auditory and other
efferents from the thalamus, cortex and hypothalamus. In
turn, it projects to brainstem and hypothalamic regions
that regulate autonomic, endocrine and feeding responses
[178]. For example, there is evidence from immunocyto-
chemistry that it receives POMC/CART and AgRP/NPY
projections from the arcuate nucleus (Table 1; [93]). The
release of CRF and bombesin-like peptides in the amy-
gdala is markedly increased by both stress and feeding
[179]. These CRF and bombesin amygdala neurones
could be influenced by arcuate POMC or AgRP projec-
tions to the amygdala triggered by either stress or altera-
tion in nutritional balance [93].
Discussion
Polygenic traits, such as obesity, result from complex
combinations of multiple contributing genes [180], envi-
ronmental factors [181], or gene-environment interac-
tions [182]. In 1980, 8% of women and 6% of men in
England were obese, with a body-mass index greater moreNutrition & Metabolism 2007, 4:18 http://www.nutritionandmetabolism.com/content/4/1/18
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than 30 kg/m2. By 1998, the proportion of obese subjects
had increased to 21% of women and 17% of men, sug-
gesting perhaps that environment is a key factor [183].
However, several rare monogenic human obesity syn-
dromes have recently been described. These include defi-
ciencies of leptin, LEPRB, single-minded 1 (SIM1), PC1,
POMC  and  MC4R  deficiency [184]. All of these syn-
dromes are associated with hyperphagia. The last three of
these gene defects produce altered protein products
involved in POMC neuronal transmission (Figure 1). The
other three are key factors interacting with the central
melanocortin pathway. Leptin binding to LEPRB is the
main peripheral hormonal stimulus to arcuate POMC
neurones [11] and SIM1 is specifically involved in the
development of the PVN [185]. The PVN is the destina-
tion of the principal arcuate POMC projection involved in
suppressing feeding [47,62,93]. sim1 heterozygous defi-
cient mice have a similar phenotype to MC4R deficient
and lethal yellow mice, with obesity resistant to the effects
of melanocortins [186]. Also, when the melanocortin
antagonist AgRP is mutated in either rodents or humans,
it leads to thinness [53-55]. Thus, there is considerable
human and murine genetic evidence for the involvement
of the central melanocortin pathways in the control of
appetite [7]. Could genetic variation in this system (and
that of related interacting molecules) be part of the poly-
genic tendency to obesity in humans [7,40,41,44-
46,129,180,184]? MC4R deficiency is the commonest of
all the human single-gene defects causing obesity, respon-
sible for 5% of all severe cases [7]. POMC heterozygosity
has also been found to correlate with obesity in mice and
humans, to a lesser extent than the homozygous state
[9,187]. POMC neurones may mediate a central anorexic
signal in proportion to body adipocyte reserves, possibly
via the actions of β-MSH on the MC4R in humans
[41,129].
Conclusion
In summary, the likely model for the melanocortin regu-
lation of feeding is that the AgRP signal in the arcuate
nucleus fluctuates to modulate a more constant POMC
signal [57,59], which is a function of the relatively steady
hormonal level of leptin [49]. POMC products may be
released differentially in the different hypothalamic and
extra-hypothalamic sites involved with feeding in the CNS
[42], which could lead to subtle variations in the anorexic
signal being transmitted. This may or may not be inde-
pendent of leptin signalling.
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